Buprenorphine prescribing after DATA-Waiver removal
Customize your policy alerts
Sign up for all sanfranciscohealthplan policy alerts
Know when sanfranciscohealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
Explains DEA removal of the DATA-Waiver (X-Waiver) and the resulting change that standard DEA registration with Schedule III authority is sufficient for prescribing buprenorphine for opioid use disorder; affects practitioners who prescribe controlled substances and members/providers of San Francisco Health Plan.
The DATA-Waiver (X-Waiver) registration numbers are no longer needed for any buprenorphine prescription.
Any practitioner with a current DEA registration that includes Schedule III authority may now prescribe buprenorphine for OUD.
New DEA training requirements (an eight-hour addiction identification and treatment training) will take effect for prescribers when applying for or renewing DEA registration on June 21, 2023.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.